Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 12.8%

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 31,400 shares, a decline of 12.8% from the November 15th total of 36,000 shares. Based on an average daily trading volume, of 54,200 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Evaxion Biotech A/S Trading Down 8.9 %

NASDAQ:EVAX traded down $0.09 on Tuesday, hitting $0.96. The stock had a trading volume of 153,265 shares, compared to its average volume of 209,099. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The stock has a market cap of $5.61 million, a price-to-earnings ratio of -3.24 and a beta of -0.39. The company has a fifty day moving average price of $2.08 and a two-hundred day moving average price of $2.70. Evaxion Biotech A/S has a 1-year low of $0.91 and a 1-year high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $0.19 million. Equities research analysts expect that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.